Provided by Tiger Fintech (Singapore) Pte. Ltd.

Humacyte, Inc.

3.03
-0.1200-3.81%
Volume:1.34M
Turnover:4.22M
Market Cap:389.87M
PE:-2.23
High:3.29
Open:3.00
Low:3.00
Close:3.15
Loading ...

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
21 Nov 2024

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery

GlobeNewswire
·
21 Nov 2024

HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

TIPRANKS
·
21 Nov 2024

Humacyte Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Nov 2024

Humacyte’s sdATEV device shows efficacy in artery bypass trial in primates

TIPRANKS
·
18 Nov 2024

Humacyte Prices $15 Million Registered Direct Offering

MT Newswires Live
·
14 Nov 2024

Humacyte prices 2.8M shares at $5.34 in registered direct offering

TIPRANKS
·
14 Nov 2024

BRIEF-Humacyte Announces Pricing Of $15.0 Million Registered Direct Offering

Reuters
·
14 Nov 2024

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

THOMSON REUTERS
·
14 Nov 2024

Humacyte Inc - to Sell 2,808,988 Shares and Warrants

THOMSON REUTERS
·
14 Nov 2024

Humacyte Announces Pricing of $15.0 Million Registered Direct Offering

GlobeNewswire
·
14 Nov 2024

Humacyte Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
13 Nov 2024

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 Nov 2024

Benchmark Co. Sticks to Their Buy Rating for Humacyte (HUMA)

TIPRANKS
·
11 Nov 2024

Humacyte Faces Financial Uncertainty: Potential Impact on Share Price and Capital

TIPRANKS
·
10 Nov 2024

Humacyte rises 6% as regulators reviewing bioengineered human tissue asset

seekingalpha
·
09 Nov 2024